Delivery Order SPE2DB22D3011-SPE2DB24FQ1JA

Award Date 5/17/24
Potential Completion Date 5/20/24
Potential Value $9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,653.31, is a delivery order for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for the treatment of diabetes. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $59,377.14, is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of January 15, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The $5,728.54 firm-fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of May 29, 2024. This award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This is a federal contract award by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation's Corporate Office division. The $1,741.62 firm fixed price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables the DLA to procure a comprehensive range of medical commodities from...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,879.98 firm fixed-price delivery order contract is for OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, with a period of performance through February 12, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,991.18 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, with an ultimate completion date of October 11, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract has a ceiling value of $1,879.98 and is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC covers a comprehensive range of pharmaceutical products and medical supplies, including specialty medications,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,422.79 firm-fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a prescription medication. The contract has an ultimate completion date of November 6, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $18,058.65, is a Firm Fixed Price Delivery Order for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of January 31, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $3,483.24, is a delivery order for OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to treat diabetes. The contract has a completion date of November 18, 2024 and is a firm fixed-price contract. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB24FQ1JA
    Delivery Order

This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, from the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $8,956.92, is for the procurement of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a pharmaceutical product. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a primary mechanism for the DLA to acquire a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/16/25, 12:26 PM